title: Allogeneic stem cell transplantation versus chemotherapy as post-remission therapy for intermediate or poor risk adult acute myeloid leukemia: results of the JALSG AML97 study.
abstract: We prospectively compared allogeneic hematopoietic stem cell transplantation (allo-HSCT) with chemotherapy as a post-remission therapy in a multicenter trial (JALSG AML97) of adult patients with intermediate or poor risk acute myeloid leukemia (AML). Of 503 patients aged 15-50 years old registered between December 1997 and July 2001, 392 achieved complete remission (CR). CR patients classified in the intermediate or poor risk group using a new scoring system were tissue typed. Seventy-three with and 92 without an HLA-identical sibling were assigned to the donor and no-donor groups. Of 73 patients in the donor group, 38 (52%) received allo-HSCT during CR1 and 17 (23%) after relapse. Intention-to-treat analysis revealed that the relapse incidence was reduced in the donor group (52 vs. 77%; p = 0.008), and the disease-free survival (DFS) improved (39 vs. 19%; p = 0.016), but overall survival (OS) was not significantly different (46 vs. 29%; p = 0.088). The OS benefit was seen in the patients aged 36-50 years old (49 vs. 24%; p = 0.031), suggesting an advantage of allo-HSCT among older patients with leukemia that is more resistant to chemotherapy than that among younger patients.
authors.affiliation: Division of Hematology, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. sakamaki-h@cick.jp
authors.forename: Hisashi
authors.initials: H
authors.lastname: Sakamaki
authors.forename: Shuichi
authors.initials: S
authors.lastname: Miyawaki
authors.forename: Shigeki
authors.initials: S
authors.lastname: Ohtake
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Emi
authors.forename: Fumiharu
authors.initials: F
authors.lastname: Yagasaki
authors.forename: Kinuko
authors.initials: K
authors.lastname: Mitani
authors.forename: Shin
authors.initials: S
authors.lastname: Matsuda
authors.forename: Yuji
authors.initials: Y
authors.lastname: Kishimoto
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Miyazaki
authors.forename: Norio
authors.initials: N
authors.lastname: Asou
authors.forename: Masatomo
authors.initials: M
authors.lastname: Takahashi
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ogawa
authors.forename: Sumihisa
authors.initials: S
authors.lastname: Honda
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Ohno
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015994:Incidence; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012307:Risk Factors; D016019:Survival Analysis; D014184:Transplantation, Homologous
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine